LY411575 is a selective, cell permeable, small molecule gamma secretase inhibitor with an IC50 of 0.1 nM for APP23 and APP51/16 primary neurons. LY411575 has been exhibited to promote goblet cell differentiation in mice intestine. Concurrently, LY411575 prevents the proliferation of the cell proliferation. LY411575 has also been observed to promote neural differentiation of mouse embryonic stem (ES) cells3. The gamma-secretase inhibitor LY411575 was injected to C57BL/6 and TgCRND8 APP transgenic mice for 15 days. Although most tissues were unaffected, doses of LY411575 which prevented the production of A¦Â had significant effects on lymphocyte development and on the intestine. LY411575 decreased overall thymic cellularity and impaired intrathymic differentiation at the CD4-CD8-CD44+CD25+ precursor stage. No effects on peripheral T cell populations were observed following LY411575 treatment, but evidence for the altered maturation of peripheral B cells was observed. In the intestine, LY411575 treatment increased goblet cell number and drastically altered tissue morphology. These effects of LY411575 were not noted in mice that were administered LY-D, a diastereoisomer of LY411575, which is a very weak ¦Ã-secretase inhibitor.

June 21, 2017

prudect name : LY411575 is a selective, cell permeable, small molecule gamma secretase inhibitor with an IC50 of 0.1 nM for APP23 and APP51/16 primary neurons. LY411575 has been exhibited to promote goblet cell differentiation in mice intestine. Concurrently, LY411575 prevents the proliferation of the cell proliferation. LY411575 has also been observed to promote neural differentiation of mouse embryonic stem (ES) cells3. The gamma-secretase inhibitor LY411575 was injected to C57BL/6 and TgCRND8 APP transgenic mice for 15 days. Although most tissues were unaffected, doses of LY411575 which prevented the production of A¦Â had significant effects on lymphocyte development and on the intestine. LY411575 decreased overall thymic cellularity and impaired intrathymic differentiation at the CD4-CD8-CD44+CD25+ precursor stage. No effects on peripheral T cell populations were observed following LY411575 treatment, but evidence for the altered maturation of peripheral B cells was observed. In the intestine, LY411575 treatment increased goblet cell number and drastically altered tissue morphology. These effects of LY411575 were not noted in mice that were administered LY-D, a diastereoisomer of LY411575, which is a very weak ¦Ã-secretase inhibitor.
LY411575

Synonyms: CAS NO: 209984-57-6Molecular Formula: C26H23F2N3O4Molecular Weight: 479.48Purity: 98% minSolubility: In DMSOStorage: −20°C


web site: www.medchemexpress.com

References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18524892